Landolt Alex M, Lomax Nicoletta, Scheib Stefan G, Girard Jürg
Klinik im Park, Zurich, Switzerland.
J Neurosurg. 2006 Dec;105 Suppl:31-6. doi: 10.3171/sup.2006.105.7.31.
Acromegaly that has not been cured by microsurgery is usually treated with fractionated radiotherapy; however, it is not possible to repeat such a treatment with effective radiation doses if it should fail. The authors pose the question: Can stereotactic radiosurgery be used as an effective, alternative method for retreatment by irradiation?
A retrospective study of 12 patients was performed to compare patients treated with Gamma Knife surgery (GKS) after initial, failed radiotherapy and 37 patients treated with GKS only. The mean dose for the initial fractionated radiotherapy was 44.6 Gy (range 40-54 Gy). The mean maximum GKS dose was 45.1 Gy (range 27-50 Gy) in the pretreated group and 49.5 Gy (range 25-70 Gy) in the group undergoing GKS alone. The mean interval between the two treatments was 10.6 years (range 3-20.6 years). The age-related insulin-like growth factor-I (IGF-I), assessed at 3-month intervals, was the main follow-up parameter. An IGF-I normalization rate of more than 80% was achieved in both patient groups; however, the latency of endocrinological normalization was longer in the patients who had undergone failed fractionated radiotherapy (median time to cure 35.4 months compared with 13.5 months).
Treatment with GKS is successful in patients with acromegaly even after failed fractionated radiotherapy; GKS represents a therapeutic tool in patients with no therapeutic options life-long octreotide. It must be noted that the incidence of neurological complications is higher (p < 0.01, 2 x 2 crosstab). The remaining dose fraction after previous fractionated radiotherapy appears to be approximately 50%. Maintenance of other endocrinological functions may be better after GKS alone; however, the difference is not significant.
经显微手术未治愈的肢端肥大症通常采用分次放射治疗;然而,如果治疗失败,无法再次给予有效放射剂量进行此类治疗。作者提出问题:立体定向放射外科能否作为一种有效的替代方法用于再次放射治疗?
对12例患者进行回顾性研究,比较初次放疗失败后接受伽玛刀手术(GKS)治疗的患者与仅接受GKS治疗的37例患者。初次分次放射治疗的平均剂量为44.6 Gy(范围40 - 54 Gy)。预处理组GKS的平均最大剂量为45.1 Gy(范围27 - 50 Gy),单纯接受GKS治疗组为49.5 Gy(范围25 - 70 Gy)。两次治疗的平均间隔时间为10.6年(范围3 - 20.6年)。以每隔3个月评估的年龄相关胰岛素样生长因子-I(IGF-I)作为主要随访参数。两组患者的IGF-I正常化率均超过80%;然而,分次放射治疗失败的患者内分泌功能正常化的潜伏期更长(治愈的中位时间为35.4个月,而单纯GKS治疗组为13.5个月)。
即使在分次放射治疗失败后,GKS治疗肢端肥大症患者仍取得成功;GKS是那些没有终身使用奥曲肽治疗选择的患者的一种治疗手段。必须注意的是,神经并发症的发生率更高(p < 0.01,2×2列联表)。先前分次放射治疗后的剩余剂量部分似乎约为50%。单纯GKS治疗后其他内分泌功能的维持可能更好;然而,差异不显著。